Molecular Historical Income Statement

MOLN Stock  USD 3.87  0.16  4.31%   
Historical analysis of Molecular Partners income statement accounts such as Total Revenue of 6.7 M can show how well Molecular Partners AG performed in making a profits. Evaluating Molecular Partners income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Molecular Partners's future profits or losses.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Molecular Partners latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Molecular Partners is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Molecular Income Statement Analysis

Molecular Partners Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Molecular Partners shareholders. The income statement also shows Molecular investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Molecular Partners Income Statement Chart

Molecular Partners AG Income Statement is one of the three primary financial statements used for reporting Molecular's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Molecular Partners revenue and expense. Molecular Partners Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Molecular Partners' Net Interest Income is very stable compared to the past year. As of the 17th of May 2024, Interest Income is likely to grow to about 4 M, while Depreciation And Amortization is likely to drop about 2.1 M.

Total Revenue

Total revenue comprises all receipts Molecular Partners generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Molecular Partners. It is also known as Molecular Partners overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from Molecular Partners' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At this time, Molecular Partners' Net Interest Income is very stable compared to the past year. As of the 17th of May 2024, Interest Income is likely to grow to about 4 M, while Depreciation And Amortization is likely to drop about 2.1 M.
 2021 2022 2023 2024 (projected)
Interest Expense548K605K49K46.6K
Depreciation And Amortization2.7M3.5M2.4M2.1M

Molecular Partners income statement Correlations

0.180.820.29-0.170.85-0.07-0.080.83-0.050.910.86-0.08-0.06-0.08-0.150.240.310.160.92-0.67
0.180.360.450.280.380.290.290.390.30.330.40.290.160.29-0.16-0.43-0.370.40.12-0.29
0.820.360.39-0.070.94-0.01-0.020.870.00.90.93-0.010.11-0.01-0.290.360.450.270.79-0.8
0.290.450.390.880.20.910.910.110.920.160.210.910.330.91-0.16-0.18-0.110.980.11-0.2
-0.170.28-0.070.88-0.290.990.99-0.370.99-0.33-0.280.990.380.99-0.04-0.34-0.30.93-0.360.24
0.850.380.940.2-0.29-0.23-0.230.98-0.210.981.0-0.23-0.03-0.23-0.290.280.350.070.87-0.83
-0.070.29-0.010.910.99-0.231.0-0.311.0-0.25-0.221.00.341.0-0.02-0.33-0.290.94-0.260.17
-0.080.29-0.020.910.99-0.231.0-0.311.0-0.25-0.221.00.341.0-0.02-0.33-0.290.94-0.260.17
0.830.390.870.11-0.370.98-0.31-0.31-0.290.970.99-0.31-0.09-0.31-0.280.20.27-0.010.85-0.8
-0.050.30.00.920.99-0.211.01.0-0.29-0.23-0.21.00.341.0-0.03-0.32-0.280.95-0.240.15
0.910.330.90.16-0.330.98-0.25-0.250.97-0.230.98-0.26-0.13-0.26-0.20.240.320.020.94-0.83
0.860.40.930.21-0.281.0-0.22-0.220.99-0.20.98-0.22-0.03-0.22-0.290.260.330.080.86-0.83
-0.080.29-0.010.910.99-0.231.01.0-0.311.0-0.26-0.220.381.0-0.05-0.33-0.280.94-0.270.18
-0.060.160.110.330.38-0.030.340.34-0.090.34-0.13-0.030.380.38-0.730.00.010.39-0.230.23
-0.080.29-0.010.910.99-0.231.01.0-0.311.0-0.26-0.221.00.38-0.05-0.33-0.280.94-0.270.18
-0.15-0.16-0.29-0.16-0.04-0.29-0.02-0.02-0.28-0.03-0.2-0.29-0.05-0.73-0.05-0.24-0.26-0.13-0.140.22
0.24-0.430.36-0.18-0.340.28-0.33-0.330.2-0.320.240.26-0.330.0-0.33-0.240.99-0.220.34-0.4
0.31-0.370.45-0.11-0.30.35-0.29-0.290.27-0.280.320.33-0.280.01-0.28-0.260.99-0.160.41-0.48
0.160.40.270.980.930.070.940.94-0.010.950.020.080.940.390.94-0.13-0.22-0.16-0.05-0.03
0.920.120.790.11-0.360.87-0.26-0.260.85-0.240.940.86-0.27-0.23-0.27-0.140.340.41-0.05-0.86
-0.67-0.29-0.8-0.20.24-0.830.170.17-0.80.15-0.83-0.830.180.230.180.22-0.4-0.48-0.03-0.86
Click cells to compare fundamentals

Molecular Partners Account Relationship Matchups

Molecular Partners income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization4.0M3.2M2.7M3.5M2.4M2.1M
Interest Expense27K271K548K605K49K46.6K
Selling General Administrative13.2M11.0M16.9M21.8M19.0M12.2M
Total Revenue20.4M9.3M9.3M189.6M7.0M6.7M
Gross Profit(23.1M)(46.7M)(46.4M)138.8M(40.8M)(38.8M)
Other Operating Expenses57.0M67.7M72.7M72.9M68.1M55.6M
Operating Income(36.7M)(58.3M)(63.4M)116.6M(61.1M)(58.1M)
Ebit(36.7M)(58.3M)(63.4M)116.6M(61.1M)(58.1M)
Research Development43.5M56.1M55.7M50.7M46.7M42.7M
Ebitda(32.7M)(55.1M)(60.8M)120.1M(58.7M)(55.8M)
Cost Of Revenue43.5M56.1M55.7M50.7M47.8M30.4M
Total Operating Expenses57.0M67.7M72.7M72.9M65.7M55.4M
Income Before Tax(36.3M)(62.8M)(63.8M)117.9M(62.0M)(58.9M)
Total Other Income Expense Net389K(4.4M)(365K)1.2M(876K)(919.8K)
Net Income(36.3M)(62.8M)(63.8M)117.9M(62.0M)(58.9M)
Income Tax Expense17K(11K)2K(1.2M)(1.1M)(1.1M)
Net Interest Income1.5M64K(457K)523K3.7M3.9M
Interest Income1.6M367K99K1.1M3.8M4.0M
Net Income From Continuing Ops(36.3M)(62.8M)(63.8M)117.9M(59.6M)(56.7M)
Reconciled Depreciation2.5M2.9M2.6M2.4M2.4M2.3M
Net Income Applicable To Common Shares(36.3M)(62.8M)(63.8M)117.9M135.5M142.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Molecular Stock analysis

When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.215
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.17)
Return On Equity
(0.30)
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.